Supporting Research
As of 2022, Canada has one approved medical treatment for FOP, a medication called Sohonos. It is believed to minimize the amount of ossification that occurs through FOP flare-ups. Other potential FOP medications are currently the focus of pre-clinical and clinical testing.
For information about how to take part in clinical testing of FOP medications, please see the information provided by the International FOP Associations at the following link: https://www.ifopa.org/about-clinical-trialswww.ifopa.org/about-clinical-trials CFOPN raises funds to support research as listed below: University of Pennsylvania, Centre for FOP Research The Center for Research in FOP & Related Disorders is the world’s first and only comprehensive research program in FOP. The activities of The Center are broad and comprehensive and focused on seven spheres of activity. For more information... University of Alberta The Canadian FOP Network and the IFOPA have joined forces to fund research conducted by rare disease experts at the University of Alberta through the IFOPA’s Competitive Research Grant (CRG) Program. The study will test DNA-like molecules known as “antisense oligonucleotides” in a mouse model of FOP, with the hope that successful completion may one day lead to clinical trials for patients with FOP. For more information.... |
|
|
|
